BioSpace News Archive

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), today announced that it has submitted its Type II variation application to the European Medicines Agency (EMA) for IMCIVREE® (setmelanotide) for the treatment of obesity and control of hunger in adult and pediatric patients six years of age and older with Bardet-Biedl syndrome (BBS) or Alström syndrome.

Arthritis Research Canada scientists have created a new grading scale to measure the severity of osteoarthritis in patients.

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”), today announced that it will report its Third Quarter 2021 results on Wednesday, October 27, 2021 after the Mexican Market (BMV) close.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2021 financial results will be released on Thursday, October 28, after the market closes.

Hologic, Inc., a global leader in women’s health, announced that it has signed a definitive agreement to acquire Bolder Surgical, a privately held, U.S.-based company that provides advanced energy vessel sealing surgical devices, for approximately $160 million, subject to working capital and other customary closing adjustments.

Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced that it will release financial results for the third quarter of 2021 after the close of trading on Thursday, November 4, 2021.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2021 financial results on Thursday, October 28, 2021, after the market close.

AbCellera (Nasdaq: ABCL) will announce its third quarter 2021 financial results on Tuesday, November 9, 2021, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases underserved by today’s therapies, announced today the submission of an investigational new drug (IND) application to the United States Food and Drug Administration (FDA).

CytRx Corporation today highlighted ImmunityBio, Inc.'s (NASDAQ: IBRX) (“ImmunityBio”) announced completion of enrollment in its Phase 2 trial studying a combination immunotherapy (Nant Cancer Vaccine)